The need for a new strategy for the treatment of multiple sclerosis.
Davison
A N
AN
Department of Neurochemistry, Institute of Neurology, Queen Square, London, UK.
D001812:Blood-Brain Barrier / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D003520:Cyclophosphamide / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000493:pharmacokinetics / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone